论文信息 - Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial - 字舞流文

Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial

J. Charrow | M. Irving | K. White | J. Hoover-Fong | C. Bacino | H. Saal | Donald G Basel | S. Kagami | K. Ozono | R. Savarirayan | F. Rutsch | P. Harmatz | Y. Alanay | M. Bober | K. Mohnike | N. Yasui | L. Polgreen | Daniel G. Hoernschemeyer | P. Arundel | E. Fisheleva | L. Tofts | Jonathan R S Day | Kala Jayaram | W. Wilcox | A. Huntsman-Labed | A. Leiva-Gea | F. Luna-González | I. Ginebreda | Rosendo Ullot Font | Dania M Porco | Hiroshi Mochizuki | Jonathan R. S. Day | K. Jayaram

[1] M. Kjelgaard‐Hansen,et al. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3–Related Skeletal Dysplasias , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[2] J. Charrow,et al. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. , 2019, The New England journal of medicine.

[3] I. M,et al. Final adult height in long-term growth hormone-treated achondroplasia patients , 2018, Yearbook of Paediatric Endocrinology.

[4] M. Aiona,et al. A degradation fragment of type X collagen is a real-time marker for bone growth velocity , 2017, Science Translational Medicine.

[5] Y. Seino,et al. Final adult height in long-term growth hormone-treated achondroplasia patients , 2017, European Journal of Pediatrics.

[6] J. Hoover-Fong,et al. A height‐for‐age growth reference for children with achondroplasia: Expanded applications and comparison with original reference data , 2017, American journal of medical genetics. Part A.

[7] A. Munnich,et al. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. , 2016, The Journal of clinical investigation.

[8] L. Johnston,et al. Optimal management of complications associated with achondroplasia , 2014, The application of clinical genetics.

[9] Y. Le Marchand-Brustel,et al. Postnatal Soluble FGFR3 Therapy Rescues Achondroplasia Symptoms and Restores Bone Growth in Mice , 2013, Science Translational Medicine.

[10] A. Munnich,et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. , 2012, American journal of human genetics.

[11] J. Hecht,et al. Achondroplasia , 2007, The Lancet.

[12] K. Nakao,et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway , 2004, Nature Medicine.

[13] D. Church,et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.